ClinicalTrials.gg
CompletedNCT07124013Updated Jan 16, 2026

A Study of Olomorasib (LY3537982) in Healthy Japanese Participants

A Phase 1 interventional study of Olomorasib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to compare and see how food affects the amount of olomorasib in the blood when olomorasib is taken in two different capsule forms. Participation in the study will last approximately 6 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participants who are overtly healthy as determined by medical evaluation including medical history, 12 lead (ECG), vital sign measurements, and clinical laboratory evaluations.
  • Have a within the range 18.5 to 30.0 kilograms per square meter (kg/m²), inclusive, at screening.
  • Participants assigned male at birth (AMAB) may participate in this study.

Exclusion criteria

Exclusion Criteria:

  • Have a history of within 5 years prior to screening except for basal cell or squamous epithelial carcinomas of the skin or in situ carcinoma of the cervix that have been resected with no evidence of disease for 3 years.
  • Have known allergies to olomorasib or any component of the formulation, or related compounds.
  • Use of any other drug or device within 30 days or 5 half-lives (if known), whichever is longer, of the first dose of study drug.
  • Have previously completed or withdrawn from this study or any other study investigating olomorasib and have previously received olomorasib
  • Show evidence of or positive hepatitis B surface antigen.
  • Show evidence of or have a positive hepatitis C virus antibody test.
  • Show evidence of infection or positive HIV antigen or HIV antibodies.
  • Show evidence of syphilis or have a positive syphilis test.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    Olomorasib Test (Part A)

    Olomorasib test formulation administered orally with or without food.

    Drug: Olomorasib

  • Experimental
    Olomorasib Reference (Part B)

    Olomorasib reference formulation administered orally with or without food.

    Drug: Olomorasib

  • Experimental
    Olomorasib Test (Part B)

    Olomorasib test formulation administered orally with or without food.

    Drug: Olomorasib

Interventions

  • Administered orally

    Also known as: LY3537982

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olomorasib

    Time frame: Day 1 (Predose) through Day 7 (72 Hours Postdose)

  2. PK: Area under the Concentration versus Time Curve from Time Zero to Time t (AUC[0-tlast]) of Olomorasib

    Time frame: Day 1 (Predose) through Day 7 (72 Hours Postdose)

07

Study locations

1 site
  • Souseikai Fukuoka Mirai Hospital
    Fukuoka, 813-0017, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Jan 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 15, 2025
StartActual
Sep 16, 2025
Primary completionActual
Jan 5, 2026
CompletionActual
Jan 5, 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07124013
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
Sep 16, 2025
Primary completion
Jan 5, 2026
Completion
Jan 5, 2026
Last update
Jan 16, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olomorasib

Start the discussion